Pavion Blue Capital’s Thermo Fisher Scientific TMO Stock Holding History

Pavion Blue Capital’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$252K	Sell	512 -21	-4%	-$11.4K	0.11%	95
2025 Q4	$309K	Sell	533 -18	-3%	-$10.2K	0.13%	82
2025 Q3	$267K	Hold	551	–	–	0.11%	86
2025 Q2	$223K	Hold	551	–	–	0.1%	96
2025 Q1	$274K	Hold	551	–	–	0.13%	81
2024 Q4	$287K	Hold	551	–	–	0.13%	79
2024 Q3	$341K	Hold	551	–	–	0.16%	73
2024 Q2	$305K	Hold	551	–	–	0.15%	76
2024 Q1	$320K	Hold	551	–	–	0.16%	76
2023 Q4	$292K	Buy	+551	New	+$267K	0.16%	76
2023 Q3	–	Sell	-551	Closed	-$287K	–	98
2023 Q2	$287K	Hold	551	–	–	0.17%	76
2023 Q1	$318K	Hold	551	–	–	0.2%	72
2022 Q4	$303K	Hold	551	–	–	0.19%	76
2022 Q3	$279K	Hold	551	–	–	0.2%	71
2022 Q2	$299K	Hold	551	–	–	0.2%	68
2022 Q1	$325K	Hold	551	–	–	0.19%	69
2021 Q4	$367K	Hold	551	–	–	0.21%	62
2021 Q3	$315K	Hold	551	–	–	0.2%	65
2021 Q2	$278K	Hold	551	–	–	0.17%	77
2021 Q1	$251K	Hold	551	–	–	0.17%	76
2020 Q4	$257K	Hold	551	–	–	0.18%	76
2020 Q3	$243K	Sell	551 -80	-13%	-$33.1K	0.19%	71
2020 Q2	$229K	Buy	+631	New	+$212K	0.2%	72

Other funds holding TMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pavion Blue Capital's TMO Position: Q1 2026 in Review

Pavion Blue Capital reduced its Thermo Fisher Scientific (TMO) stake by 3.9% in Q1 2026, selling an estimated $11.4K and leaving 512 shares worth $252K. The position accounts for 0.11% of the portfolio, ranked #95.

Pavion Blue Capital first reported a position in TMO in Q2 2020 and has held it in 23 quarters since. The position peaked at $367K in Q4 2021. 2,590 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

Pavion Blue Capital held 512 shares of Thermo Fisher Scientific worth $252K as of Q1 2026.
Pavion Blue Capital sold 21 Thermo Fisher Scientific shares in Q1 2026, an estimated $11.4K.
Thermo Fisher Scientific made up 0.11% of Pavion Blue Capital's portfolio in Q1 2026, its #95 holding.
Pavion Blue Capital first reported a position in Thermo Fisher Scientific in Q2 2020 and has held it in 23 quarters since.
Pavion Blue Capital's Thermo Fisher Scientific position peaked at $367K in Q4 2021.
2,590 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Pavion Blue Capital's 13F filing for Q1 2026, filed 6 May 2026.